Table A1.
Definitions of End Points Used in Table 1
| Trial ID | Primary End Point As Defined in the Primary Publication |
|---|---|
| NCCTG-844652 | Overall survival |
| RTOG-8501 | Overall survival |
| POG-9006 | Continuous complete remission rate: the time from achievement of a complete remission to failure (death, relapse, or second malignancy) |
| EST-3189 | Overall survival |
| CLB-9011 | Complete response: absence of constitutional symptoms and of lymphadenopathy, splenomegaly, and hepatomegaly on physical examination; an absolute neutrophil count of at least 1,500/μL, a platelet count of at least 100,000/μL, a hemoglobin level higher than 11 g/dL (without transfusion), and an absolute lymphocyte count of less than 4,000/μL; and bone marrow of normal cellularity, with less than 30% lymphocytes and no lymphoid nodules |
| SWOG-8892 | Progression-free survival: time from registration to the date of first observation of progressive disease or death as a result of any cause |
| ECOG-2491 | Disease-free survival: the time from the beginning of complete remission to relapse or death as a result of any cause |
| CCG-1882 | Event-free survival: the time from random assignment to relapse at any site, a second malignant neoplasm, or death during remission |
| SWOG-8814 | Disease-free survival: the time from random assignment to recurrence or death (the definition is from the study protocol; primary publication is an abstract) |
| SWOG-8797 | Overall survival |
| CLB-9344 | Disease-free survival: the time from study entry to first locoregional recurrence, first distant metastasis, or death as a result of any cause |
| RTOG-9001 | Overall survival |
| CCG-5942 | Event-free survival: the time to disease relapse, progression, occurrence of a second malignant neoplasm, or death from any cause |
| SWOG-9133 | Failure-free survival: the time from random assignment to the date of disease progression or death |
| RTOG-9413 | Progression-free survival: time to the first occurrence of local progression, regional nodal failure, distant failure, biochemical (PSA) failure, or death as a result of any cause |
| SWOG-S9701 | Progression-free survival: the time from registration to the date of first recurrence or death |
| NCCTG-N9741 | Progression-free survival: the time from study entry to disease progression. Deaths occurring within 30 days of treatment discontinuation were considered disease progression. Without contradictory data, patients who died or were lost to follow-up were assumed to have experienced progression at the time they were last known to be progression free. (This end point was referred to as “time to progression” in the primary publication) |
| NCIC-MA17 | Disease-free survival: the time from random assignment to the recurrence of the primary disease (in the breast, chest wall, or nodal metastatic sites), or the development of a new primary breast cancer in the contralateral breast; secondary cancer or death without a recurrence, or a diagnosis of contralateral breast cancer were not included as events |
| E-1496 | Progression-free survival: the time from maintenance random assignment to progression or death (the definition is from the study protocol; primary publication is an abstract) |
| E-E1A00 | Response rate: best response within four cycles of treatment (4 months from the start of treatment). Standard ECOG response criteria were used. An objective response was defined as a 50% or higher decrease in the serum and urine monoclonal protein levels from baseline. Patients with measurable disease only in the urine needed to have a greater than 90% reduction in 24-hour urine monoclonal protein excretion to be considered as having a response |
| CCG-1961 | Event-free survival: time to relapse at any site, death during remission, or a second malignant neoplasm |
| E-3200 | Overall survival |
| ECOG-2997 | Complete response: response was evaluated according to NCI Working Group Criteria (Cheson BD et al, Blood 87:4990-4997, 1996) |
| NSABP-B-31/NCCTG-N9831 | Disease-free survival: time to local, regional, and distant recurrence; contralateral breast cancer, including ductal carcinoma in situ; other second primary cancers; and death before recurrence or a second primary cancer |
| ECOG-4599 | Overall survival |
| ECOG-2100 | Progression-free survival: the time from randomization to disease progression or death from any cause |
| NCIC-MA21 | Disease-free survival: the time from random assignment to the time of recurrence of the primary disease. Local or nodal recurrence and metastatic disease are considered a recurrence of the primary tumor. Patients who have contralateral breast cancer or a second primary malignancy or die as a result of some cause other than disease will be censored as event free at the time of death (the definition is from the study protocol; primary publication is an abstract) |
Abbreviations: NCCTG, North Central Cancer Treatment Group; RTOG, Radiation Therapy Oncology Group; POG, Pediatric Oncology Group; CLB, Cancer and Leukemia Group B; SWOG, Southwest Oncology Group; ECOG, Eastern Cooperative Oncology Group; CCG, Children's Cancer Group; PSA, prostate-specific antigen; NCIC, National Cancer Institute of Canada; NCI, National Cancer Institute; NSABP, National Surgical Adjuvant Breast and Bowel Project.